化疗引起的miRNA表达的改变及其对卵巢癌的预后影响
Samruddhi Ranmale1, Pavan Kumar1, Hemant Tongaonkar2
1Department of Infectious Biology, ICMR-National Institute for Research in Reproductive and Child Health, Mumbai, India.
Frontiers in oncology
|September 8, 2025
概括
卵巢癌患者的microRNAs (miRNAs) 表达变化,其中一些与化疗效应和患者生存有关. 这些循环和组织miRNA显示出作为卵巢癌的诊断和预后生物标志物具有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 卵巢癌 (OC) 由于晚期诊断,复发和耐化学药性而导致高死亡率.
- 微RNAs (miRNAs) 是瘤发生和化学抵抗的关键调节者.
- 在OC患者中不同的miRNA表达可能为化学疗法的影响和生存预测提供见解.
研究的目的:
- 评估来自卵巢癌患者的临床样本中的差异性miRNA表达.
- 研究miRNA表达,化疗和患者生存结果之间的关联.
主要方法:
- 收集了来自127名参与者的临床样本 (化疗原始,化疗OC患者和健康对照).
- 使用定量实时PCR分析量化miRNA表达.
主要成果:
- 在接受治疗的OC患者的血清中观察到miR-182和miR-130a的升高,可能是由于化疗.
- 组织miR-182和miR-106a的升高与晚期疾病相关;miR-106a与反应不佳和复发相关.
- miR-200a的升高与转移和早期复发相关;在转移患者中发现了减少的瘤抑制剂miR-433和miR-145.
- 血清miR-130a和组织miR-20a被确定为独立的无进展生存预测因素.
- 一个血清miRNA小组 (miR-182,miR-106a,miR-23b) 显示了诊断潜力 (AUC=0.743).
结论:
- 在印度OC患者中观察到循环和组织miRNAs的差异调节.
- 瘤性miRNA被选择性地保留在瘤中,而抑制瘤的miRNA被释放到循环中.
- miRNAs显示出作为卵巢癌的诊断和预后生物标志物的实用性.
相关概念视频
MicroRNAs
3.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K
MicroRNAs
23.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.9K


